BioStem appoints Jodi Ungrodt to board as audit committee chair

BioStem Technologies (OTC: BSEM) announced the appointment of Jodi Ungrodt to its Board of Directors as Chair of the Audit Committee, effective March 18, 2026. The company develops placental-derived products for wound care applications.

Ungrodt brings 29 years of financial leadership experience as a senior partner at Ernst & Young, where she advised life sciences companies on public offerings, business combinations, risk assessment and regulatory compliance. She qualifies as a financial expert under SEC, NYSE, and NASDAQ rules and has advised more than 30 initial public offerings during her career.

As Audit Committee Chair, Ungrodt will oversee the company's financial reporting, internal controls and risk management practices. She previously served as Chair of the Audit Committee for Feeding San Diego for over a decade and currently serves as an Advisory Board Member for Life Science Cares. During her tenure at Ernst & Young, she served more than 70 companies in the life sciences sector.

Ungrodt holds a BS in Accounting from San Diego State University and is a Certified Public Accountant. She is a member of the American Institute of Public Accountants and the California Society of CPAs.

The appointment follows Brandon Poe's transition from the board to chief financial officer in August 2025. Poe had served on BioStem's Board of Directors for three years and brings more than 25 years of finance leadership experience in healthcare and life sciences.

The information is based on a company press release statement.

You May Also Be Interested In

• Exclusive: National Vision’s CEO on why the market got post-Q1 selloff wrong
• Odysight.ai says it won't use ATM offering near current share price
• Diana Shipping raises Genco bid to $27.34 per share